RE:Hope for the Best, this is a viable path forward " it arguably values CZO's at a target price between C$1.25-C$2.20 per CZO share. That would obviously take PGX into account "
When AEZS announces its diagnostic deal given that CZO has been valued the same as AEZS in the merger it will help the market see the value of CZO by implication. With AEZS's clinical trial expected to be fully enrolled by the end of 2023 a diagnostic deal could be very close. About six months ago AEZS said in a news release: "...based upon our active outreach and discussions, we expect to secure an alternate development and commercialization partner for Macrilen® for the U.S. and Canada.” As a member of the Board of Directors Gilles is well positioned to know what has been discussed. To further de-risk the diagnostic test they could wait until regulatory approval expected later this year. AEZS could also have 'go'/'no go' clinical trial decisions approaching. It could define its clinical programs and what they are expected to achieve as value catalysts.